Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004;27(12):857-70.
doi: 10.2165/00002018-200427120-00003.

Data quality management in pharmacovigilance

Affiliations
Review

Data quality management in pharmacovigilance

Marie Lindquist. Drug Saf. 2004.

Abstract

Pharmacovigilance relies on information gathered from the collection of individual case safety reports and other pharmacoepidemiological data. Even given the inherent limitations of spontaneous reports, the usefulness of this data source can be improved with good data quality management. Although under-reporting cannot be remedied this way, the negative impact of incomplete reports, which is another serious problem in pharmacovigilance, can be reduced. Quality management consists of quality planning, quality control, quality assurance and quality improvements. The pharmacovigilance data processing cycle starts with data collection and, in computerised systems, data entry; the next step is data storage and maintenance; followed by data selection, retrieval and manipulation. The resulting data output is analysed and assessed. Finally, conclusions are drawn and decisions made. The increased knowledge feeds back into the data processing cycle. Focussing on the first three steps of the data processing cycle, the different quality dimensions associated with these steps are described in this review, together with examples relevant to pharmacovigilance data. Functioning, well documented, and transparent quality management systems will benefit not only those involved in data collection, management and output production, but, ultimately, also the pharmacovigilance end users, the patients.

PubMed Disclaimer

References

    1. Drug Intell Clin Pharm. 1988 Feb;22(2):157-61 - PubMed
    1. Drug Saf. 2000 Dec;23(6):533-42 - PubMed
    1. Pharmacol Toxicol. 2000;86 Suppl 1:20-2 - PubMed
    1. Pharmacol Toxicol. 2000;86 Suppl 1:16-9 - PubMed
    1. Br J Clin Pharmacol. 1993 Apr;35(4):400-8 - PubMed

MeSH terms

LinkOut - more resources